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Glycogen storage disease type II (GSDII; Pompe
disease), caused by inherited deficiency of acid
α-glucosidase, is a lysosomal disorder affecting heart
and skeletal muscles. A mouse model of this disease
was obtained by targeted disruption of the murine acid
α-glucosidase gene (Gaa) in embryonic stem cells.
Homozygous knockout mice (Gaa –/–) lack Gaa mRNA
and have a virtually complete acid α-glucosidase
deficiency. Glycogen-containing lysosomes are detected
soon after birth in liver, heart and skeletal muscle cells.
By 13 weeks of age, large focal deposits of glycogen
have formed. Vacuolar spaces stain positive for acid
phosphatase as a sign of lysosomal pathology. Both
male and female knockout mice are fertile and can be
intercrossed to produce progeny. The first born
knockout mice are at present 9 months old. Overt clinical
symptoms are still absent, but the heart is typically
enlarged and the electrocardiogram is abnormal. The
mouse model will help greatly to understand the
pathogenic mechanism of GSDII and is a valuable
instrument to explore the efficacy of different therapeutic
interventions.
INTRODUCTION
Heart disease and skeletal muscle disorders are life threatening
and often incurable. They have become the subject of a gamut of
therapeutic studies in which animal models play a crucial role, be
it for the development of drug, transplantation, enzyme or gene
therapy. Here, we report on the generation of a knockout mouse
model of glycogen storage disease type II (GSDII; Pompe
disease) with obvious involvement of heart and skeletal muscle.
GSDII is a fatal disorder with a characteristic progressive loss
of skeletal and/or heart muscle function (1). Early and late onset
subtypes are distinguished. The infantile or generalized form of
the disease presents in the first few months of life with
cardiomyopathy and hypotonia. There is moderate enlargement
of the liver, without serious impairment of liver function. Patients
die before the age of 2 years by cardiorespiratory failure (2,3).
Milder forms of the disease are characterized by skeletal muscle
weakness in the absence of cardiac symptoms and are easily
misdiagnosed as muscular dystrophy or limb girdle dystrophy
(4). Most patients become wheelchair bound and/or dependent on
artificial ventilation. There is no effective therapy for any form of
this disease.
GSDII is inherited in an autosomal recessive mode. At the very
basis of this disease are mutations in the acid α-glucosidase gene
(GAA) (5,6) that fully or in part prohibit the biosynthesis of acid
α-glucosidase and thereby the degradation of lysosomal
glycogen. The clinical phenotype is largely determined by the
combination of mutant alleles and the resulting level of residual
acid α-glucosidase activity (7,8). Infantile patients show virtually
no activity, whereas older and more mildly affected patients have
enzyme activity levels up to 25% of the control value (8).
The extent of lysosomal glycogen storage is concordantly
different. Infantile patients have massive storage in many tissues
including heart, skeletal muscle, smooth muscle, liver, kidney and
the peripheral and central nervous system (1,3,9–12). In late
onset GSDII, there is minimal to no storage of glycogen in tissues
other than skeletal muscle (13).
Despite the fact that this disease has been known for many
years, questions concerning its pathogenesis have remained. This
was one reason for us to invest in the generation of a laboratory
mouse model. A second reason was the need to have a versatile
animal model for testing the efficacy of innovative therapeutic
developments such as enzyme and gene therapy.
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RESULTS
Targeted disruption of the Gaa gene and generation of
Gaa (–/–) mice
The rationale for making a mouse model of GSDII via targeted
disruption of the acid α-glucosidase (Gaa) gene is the 84%
identity of the murine and human acid α-glucosidase amino acid
sequences (14) indicating conservation of enzyme function. For
this purpose, a 6.8 kb Asp718 fragment containing exon 5–14 of
the murine Gaa gene was isolated from a 129 genomic library. To
disrupt the murine Gaa gene, a neo cassette was inserted in the
unique EagI site in exon 13 of the genomic fragment. The tk
cassette for counter selection was positioned at the 5′ end. Both
cassettes are orientated in the same direction as the Gaa gene
(Fig. 1A). The construct was introduced into the E14 embryonic
stem (ES) cell line by electroporation, and 137 clones were picked
after positive and negative selection. Twenty-two clones were
positive for homologous recombination according to PCR
analysis as described in Materials and Methods (targeting
frequency of 16%). Seven of these were tested further by
Southern blotting, after NcoI digestion. The blot was hybridized
with the neo sequence as probe resulting in a 2.6 kb fragment
indicative of homologous recombination (data not shown). The
clones were karyotyped. Three clones were euploid and had
correct homologous recombination. Two of these (15.1D and
17.5D) were injected into blastocysts. Six chimeric mice were
identified by coat colour, five males and one female. The males
were mated with C57BL/6 and FVB females. Four males
appeared to be germline transmitters. The heterozygous offspring
were intercrossed, and their offspring were tested by PCR
analysis with primers m8–m9 and nested PCR to discriminate
between homozygous knockout (–/–), heterozygous knockout
(+/–) and wild-type (+/+) offspring (Fig. 1B). Genotyping of 274
offspring from heterozygous crosses revealed a frequency of
22.6% for homozygous knockout mice compatible with the
expected Mendelian frequency (25%). The α-glucosidase knock-
out mice, both females and males, are fertile and produce normal
litter sizes. No differences were observed between mice derived
from the two different clones or the different inbred strains.
Analysis of gene products of GSDII knockout mice
No correct Gaa mRNA is produced by cultured cells of
homozygous knockout mice as illustrated by reverse
transcription-PCR analysis using primer set m8–m4 (Fig. 1C).
Instead, there is an abnormal messenger in which acid α-glucosidase
sequences are linked to sequences of the neo cassette (Fig. 1C;
primer set n2–m4). RT-PCR with primers RT2 in exon 4 and n1 in
the neo cassette revealed expression of a correctly spliced
recombinant messenger (data not shown). For each RT reaction, the
amplification of α-actin mRNA was performed as control. In
accordance with the absence of a normal acid α-glucosidase
transcript, the enzyme activity is virtually fully deficient in the
cultured cells and in the organs of knockout mice, the exception is
the intestine due to the sucrase–isomaltase activity in this tissue
(Table 1). Cells and tissues of heterozygous mice have intermediate
activity levels. The data in Table 1 are activities measured with
the artificial substrate 4-methylumbelliferyl-α-D-glucopyranoside
(4MU) at a suboptimal pH of 3.6 (instead of 4.3) to reduce the
interference of neutral α-glucosidase isozymes. The deficiency of
acid α-glucosidase in organs of homozygous knockout mice was
confirmed by Western blotting. Figure 1D shows expression of a 65
kDa acid α-glucosidase (arrow) in all tissues of wild-type mice and
an additional 70 kDa form in skeletal muscle, brain and intestine. No
trace of acid α-glucosidase is detectable in tissues of homozygous
knockout mice, while the method is sensitive enough to detect 3%
of wild-type activity. The cultured cells are also devoid of acid
α-glucosidase, as demonstrated by immunofluorescence micro-
scopy (Fig. 2A and B).
Table 1. Acid α-glucosidase activity in tissues of wild-type, heterozygous
and knockout mice
Tissue Acid α-glucosidase activity (nmol 4MU/mg/h)
Wild-type Heterozygote Knockout
Cultured cells 129.0 73.2 2.5 (1.9)
Liver 29.2 13.7 0.6 (2.0)
Spleen 7.4 3.5 0.2 (2.6)
Kidney 31.9 19.5 0.6 (1.9)
Intestine 70.1 53.0 51.9 (74.0)
Thymus 9.8 3.4 0.3 (2.1)
Lung 8.4 3.0 0.3 (3.6)
Heart 5.6 1.8 0.2 (3.8)
Triceps 8.7 4.7 0.2 (1.8)
Femoral muscle 7.8 4.5 0.2 (2.6)
Sural muscle 6.2 4.8 0.2 (2.6)
Tongue 10.3 6.3 0.1 (1.3)
Cerebellum 39.6 17.7 0.1 (0.4)
Cerebrum 47.0 21.0 0.2 (0.5)
Enzyme activity was assayed in cell lysates and tissue homogenates with the
artificial 4MU substrate at pH 3.6 and expressed per mg protein. Measurements
were performed in duplicate, and figures represent the mean of two independent
experiments. The figures in parentheses are the activities in knockout mice as
a percentage of wild-type mice.
Phenotype of the GSDII knockout mice
Clinical signs. At birth, the homozygous knockout mice were
indistinguishable from their normal littermates in terms of
physical appearance. Up until the present time (9 months after
birth), this situation has not changed. The mice still lack overt
clinical symptoms, but there is evidence of a developing
cardiomyopathy. Several knockout mice had an abnormal
electrocardiogram at 32 weeks of age with a high voltage QRS
complex, as seen in human infantile GSDII (not shown).
Radioscopy revealed cardiac enlargement which was confirmed
at autopsy (Fig. 3). The heart of a knockout mouse (right) is
round, swollen and pale compared with the smaller, oval and
darker stained heart of an unaffected littermate (left). A dilatation
of both ventricles was observed in cross-section. The pale colour
of the heart was described earlier for Corriedale sheep with
GSDII (15). The condition is called round heart disease in
affected Nicholas turkeys (16).
Tissue pathology. Animals were sacrificed at 8 days, 6 weeks and 13
weeks after birth to search for pathological changes. No macroscopic
abnormalities of organs were noted at these time points, but
microscopical changes were seen early after birth. At 8 days, the
femoral muscle is morphologically unaffected (Fig. 2C; stained
with methylene blue), but some muscle fibres contain groups of
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Figure 1. Generation of α-glucosidase-deficient mice by homologous recombination. (A) Partial structure of the murine Gaa gene (top), the targeting vector (middle)
and the predicted structure of the homologous recombined locus (bottom). Asp718 and NcoI are the relevant restriction sites. The primer positions are indicated. (B)
Analysis of genomic DNA from tail. The left panel with the primer combination m8–m9 discriminates between wild-type (+/+), heterozygous (+/–) and homozygous
knockout (–/–) mice, containing respectively only the wild-type (690 bp), the wild-type and targeted (2200 bp) and only the targeted allele. The nested PCR (right panel)
with n4–m3 as the first and n2–m2 as the second primer set identifies the targeted allele (2200 bp) in the heterozygous (+/–) and homozygous (–/–) knockout mice.
(C) RT-PCR analysis of mRNA extracted from cultured cells of wild-type (+/+), heterozygous (+/–) and homozygous knockout (–/–) mice using primer sets m8–m4
and n2–m4. The first primer set shows the absence of normal mRNA in homozygous knockout mice (–/–), the second the presence of a fusion product of neo and
acid α-glucosidase sequences. (D) Western blot analysis of Gaa expression. Acid α-glucosidase was immunoprecipitated from tissue homogenates with rabbit
anti-human acid α-glucosidase antibodies and applied to SDS–PAGE. After subsequent blotting, acid α-glucosidase was visualized with the same antibodies and
chemiluminescence staining. Human placental acid α-glucosidase was applied as molecular marker. Arrows indicate the position of (cross-reacting) murine acid
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Figure 3. Comparative morphology of the hearts of wild-type (left) and knockout (right) littermates at 32 weeks of age. Note the ventricular hypertrophy and the pale
colour of the heart of the afflicted animal.
dark granules (arrow) not present in muscle fibres of wild-type
mice of the same age. Similar granules were observed by Cardiff
et al. (9) in muscle of a patient with GSDII. Conclusive
information on the lysosomal accumulation of glycogen was
obtained by electron microscopy. Figure 4A shows glycogen
deposits surrounded by a membrane in femoral muscle of
8-day-old mice. At 6 weeks after birth, the majority of fibres
contains numerous glycogen deposits, as illustrated in cross-
section (Fig. 2D). Large vacuoles are seen in the centre of some
fibres. Electron microscopy performed at 6 weeks confirms this
picture (not shown). The progressive nature of glycogen storage
is also illustrated in Figure 2F and G showing femoral muscle
stained with periodic acid–Schiff (PAS) reagent. Arrays of
PAS-positive material are observed 6 weeks after birth, in
between and parallel to the fibrils (Fig. 2F). At 13 weeks of age,
the PAS-positive arrays are more numerous and start to form a
continuity along the fibrils. Muscle fibres from wild-type animals
do not stain with PAS (Fig. 2E).
As another sign of progressive cellular pathology, the muscle
fibres of the homozygous knockout mice become positive for acid
phosphatase, a lysosomal marker with increased activity in
various lysosomal storage disorders and commonly used as
diagnostic marker for GSDII (13). Figure 2I illustrates this
phenomenon at 13 weeks of age, but it is already notable at 6
weeks. Similar observations were made in sural muscle, triceps
and skeletal muscle of the tongue.
Pathological signs are also manifest in heart muscle of
knockout mice. At 8 days after birth, small fields with glycogen-
containing lysosomes are observed by electron microscopy (Fig.
4B and C). Loss of organized structure of heart muscle cells is
seen at 13 weeks of age in knockout mice (Fig. 5B) compared
with wild-type (Fig. 5A). Large vacuoles have formed inside the
cells. The vacuoles are PAS positive, indicating that they are filled
with glycogen (Fig. 5C), and acid phosphatase-positive (red
colour), indicating that they are actually lysosomes (Fig. 5D).
Other tissues and cells also show lysosomal glycogen storage.
This was observed in liver of 8-day-old mice using transmission
electron microscopy (not shown). PAS-positive granules were
seen in smooth muscle cells of blood vessels (Fig. 5E), in
Schwann cells (Fig. 5F) and in anterior horn cells (Fig. 5G).
DISCUSSION
Animal models of human diseases have proven their value for
obtaining insight into pathogenic mechanisms and for testing
therapeutic drugs and innovative treatment protocols. It was for
use in these two applications that we set out to generate a mouse
model of GSDII by targeted disruption of the acid α-glucosidase
Figure 2. Cultured cells from the tail of wild-type (A) and knockout mice (B) stained for the presence of acid α-glucosidase using rabbit anti-human acid α-glucosidase
antibodies. (C) Methylene blue staining of a semi-thin (1 µm) longitudinal section of femoral muscle of an 8-day-old knockout mouse. (D) Same staining of a semi-thin
cross-section of the same type of muscle of a knockout mouse at 6 weeks of age. (E and F) PAS staining of longitudinal section of GMA-embedded femoral muscle
of a wild-type (E) and knockout mouse (F) at 6 weeks of age. (G) PAS staining of a longitudinal cryo-section of femoral muscle of a 13-week-old knockout mouse.
(H and I) Acid phosphatase staining of the same muscle of wild-type (H) and knockout (I) mice at 13 weeks of age.
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Figure 4. Electron micrographs showing lysosomal glycogen storage in an 8-day-old knockout mouse. (A) Femoral muscle fibre. (B and C) Heart muscle fibre.
Glycogen particles are dark and densely packed in lysosomes, and freely dispersed in cytoplasm. (L) lysosomes, (M) mitochondria, (N) nucleus.
gene. The naturally occurring animal models of GSDII are less
suitable for this purpose because of the physical dimension of the
animal, the long generation time and the small littersize (cattle)
(17–19) or the evolutionary distance from humans (quail) (20).
Strains of sheep (15), dogs (21,22), cats (23) and turkeys (16)
with the disease have to our knowledge not been established.
Evidence that the knockout mouse described in this study
stands as a model for human GSDII is based on the following
findings. Analysis of genomic DNA demonstrates the presence of
the disrupted Gaa gene and the absence of the normal gene. The
normal messenger is not present either. Instead, there is a
messenger in which neo sequences are linked to acid α-glucosidase
sequences. Furthermore, tissues and cultured cells of homozygous
knockout mice are fully deficient in acid α-glucosidase as judged
by immunoblotting or immunocytochemistry. Acid α-glucosidase
activity is profoundly deficient in all organs except intestine. The
residual activity in the latter organ is explained by the presence of
the intestinal enzymes sucrase and isomaltase, which share
structural homology with acid α-glucosidase. They act on the
same artificial substrate with maximal activity at neutral pH, but
exhibit residual activity at pH 3.6 (24). Heterozygous knockout
mice have 50% of the normal acid α-glucosidase activity, as
expected for an autosomal recessive trait. The best evidence that
this knockout mouse represents a model of human GSDII is the
progressive lysosomal glycogen storage and the ensuing cellular
pathology.
There are several arguments to classify this mouse model as
representative for the early-onset infantile form of GSDII. mRNA
synthesis is not detectable, the acid α-glucosidase deficiency is
virtually complete and the heart muscle is evidently involved. The
tissue pathology of the mice also points to infantile GSDII.
Knockout mice have, from birth onwards, a generalized and
progressive lysosomal storage of glycogen. At 13 weeks of age,
many muscle fibres show structural abnormalities. Large
PAS-positive vacuoles have formed between the contractile
elements. These vacuoles are in essence expanded lysosomes as
evidenced by the fact that they are acid phosphatase positive.
Moreover, there is accumulation of glycogen in motor neurons
and Schwann cells, as only observed in tissue specimens of
patients with infantile GSDII (11–13). However, in contrast to
most babies born with infantile GSDII, the knockout mice do not
develop overt clinical symptoms before adulthood.
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Figure 5. Tissue pathology and glycogen storage in knockout mice. (A–D) Heart muscle of 13-week-old mice. Haematoxylin–eosin staining shows fibre damage in tissue
of the knockout (B), but not the wild-type (A) mouse. Vacuoles in between the muscle fibres of the knockout mouse are PAS- (C) and acid phosphatase- (D) positive. (E–G)
Smooth muscle cells of blood vessels at 6 weeks of age (E), Schwann cells of peripheral nerves at 6 weeks of age (F) and anterior horn cells at 3 weeks of age (G) also contain
PAS-positive granules.
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The knockout mouse model resembles in biochemical, patho-
logical and clinical aspects the naturally occurring animal models
of GSDII. Afflicted Brahman and Shorthorn cattle (17–19),
Corriedale sheep (15), Lapland dog (21,22,25), Japanese quail
(20,26,27) and Nicholas turkey (16) have both skeletal muscle
and heart muscle involvement, like the knockout mice. Also,
lysosomal glycogen storage in neurons and Schwann cells was
described for all species, except turkey (28). Biochemical data are
only available for cattle, dog and quail. Afflicted cattle and dogs
have a complete acid α-glucosidase deficiency like the knockout
mouse model (29,30). For quail, it is unclear to what extent
lysosomal acid α-glucosidase activity contributes to the total
measured α-glucosidase activity (31–33).
Clinical parameters are more difficult to compare due to the
great diversity of the species, but it is interesting to compare the
clinical course of the disease in relation to the duration of the
gestation period, the time to maturity and the normal life span of
the species (Table 2). There is evidently no correlation between
the length of the clinical course and the time to maturity or the life
span. However, there is a striking similarity between all species
including humans, with regard to the length of the pathologic
process, which in Table 2 is defined as the arithmetic sum of the
duration of the gestation period and the life expectancy of the
affected individual. Perhaps this is not completely unexpected if
one considers that the pathological process starts for inherited
lysosomal storage disease in principle at the (one cell) embryonic
stage. If the absolute rather than the relative age of the species is
counted when comparing clinical phenotypes, it can be concluded
that all animal models resemble the human infantile form of
GSDII. This principle may hold in a similar way for animal
models of other lysosomal storage diseases, with a comparatively
late onset of symptoms (34–36). For our Gaa knockout mouse
model, it implies that clinical symptoms are likely to emerge at
around 1 year of age.
Meanwhile, the mouse model can be used for the development
of therapeutic regimens. Approaches to consider are diet, drugs,
transplantation, enzyme and gene therapy. The combination of
easy to measure glycogen concentration and acid α-glucosidase
activity gives the GSDII mouse model a wider applicability. It can
serve to test the effectiveness of various gene targeting vectors for
diseases of heart and skeletal muscle in general.
MATERIALS AND METHODS
Construction of targeting vector
The mouse Gaa cDNA (GenBank accession No. U449351) was
isolated from a mouse liver cDNA library using human acid
α-glucosidase cDNA as probe. With the murine cDNA as probe,
11 kb of the mouse Gaa gene consisting of exons 3–16 was
isolated subsequently from a mouse 129 genomic library. A
6.8 kb Asp718 genomic fragment, including exons 5–14, was
then cloned into the KpnI site of pBluescript with an adapted
polylinker, containing ClaI, SalI, KpnI, ClaI, SacI restriction
sites. A neo expression cassette with a length of 1.6 kb was
isolated from pPGKneopA (37) by digestion with EcoRI and
XhoI, blunt ends were generated and the fragment was inserted in
the blunted unique EagI site in exon 13 of the Gaa gene. The
HSV-tk expression cassette, isolated from pHA140 (38) by
digestion with SalI, was introduced in the SalI site 5′ of the
construct. Both cassettes were inserted in the sense orientation
with respect to the transcriptional orientation of the Gaa gene.
The structure of the targeting vector is shown in Figure 1A.
Gene targeting in embryonic stem cells
After ClaI digestion, the targeting construct (15–20 µg) was
separated from the vector by agarose gel electrophoresis and
isolated via electroelution. It was introduced into E14 ES cells by
electroporation, essentially as described by Bakker et al. (39).
Briefly, transfected cells were cultured in conditioned medium,
and double selection with G418 (200 µg/ml) and FIAU (2 µM)
was started 24 h after electroporation. Clones were picked 10–14
days after electroporation and screened for homologous recom-
bination by nested PCR amplification. Two primer sets were used
to amplify a 1.6 kb fragment that includes the 3′ recombination
junction. The first PCR (35 cycles, each consisting of 45 s at
94C, 1 min at 59C and 2.5 min at 68C) was performed with
primers n4 (sense, GACGAGTTCTTCTGAGGGGATCA),
complementary to a sequence in the neo cassette, and m3
(antisense, GCCTTCCTCATGGCCTGCTG), complementary to
a sequence in exon 15 immediately downstream of the Asp718
restriction site. In the nested PCR (25 cycles, with the same
temperature program) primers n2 (sense, GTGGGCTCTATGG-
CTTCTGAGG) and m2 (antisense, GCTGAACCTGTACGGC-
TCCTG) were used (Fig. 1A). Correctly recombined clones were
karyotyped according to standard procedures and tested by
Southern blotting. Genomic DNA was digested with NcoI and a
neo fragment was used as probe.
Generation of chimeric and acid α-glucosidase (–/–)
mice (GSDII knockout mice)
Two positive clones were injected into C57BL/6 blastocysts.
Chimeric mice were bred to C57BL/6 and FVB females, and the
offspring with agouti and grey coats were tested for the
transmission of the disrupted allele by the PCR described above.
Homozygous mice (–/–) were obtained by interbreeding the
heterozygotes (+/–). DNA from the tail was analysed using a PCR
(35 cycles, following the same temperature program as described
above) with primer m8 (sense, CCTCACTGAAGCTATCGCC-
TCC) in exon 12 and m9 (antisense, GCAAGATGCTCCCAAG-
AGCTCC) in exon 13 in combination with the nested PCR
described above.
Cell culture from murine tail
Tails were cut into small pieces, and the tissue was dissociated for
15 min at 37C in 10 mM sodium phosphate, 150 mM NaCl
(pH 7.1), containing 0.05% trypsin and 0.02% EDTA. After low
speed centrifugation, a fresh solution of trypsin/EDTA was added
for another 15 min. Cells and softened tissue were then
resuspended in Dulbecco’s modified Eagle’s medium (DMEM)
with 15% fetal calf serum (FCS) and antibiotics and seeded in
25 cm2 tissue culture flask, pre-coated with FCS and 1 ml of
medium. Clonal outgrowth of cells was observed 3 weeks later,
and stable cell lines were obtained after 2 months of growth.
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Table 2. Normal development and clinical course of GSDII in humans and in animal models
Species Normal development Clinical course of GSDII
Gestation Time to Average Onset of Death Duration of the
period maturity life span clinical pathologic
symptoms processa
Humanb 9 m 12–15 y 75 y 3 m 6–18 m 15–27 m
Brahman 9 m 2 y 15–20 y 3 m 8–9 m 17–18 m
Shorthorn 9 m 2 y 15–20 y 3 m 7–16 m 16–25 m
Sheep 5 m 8 m 15–20 y <6 m 6–12 m 11–17 m
Dog 2 m 12 m 15–20 y 4 m 18 m 20 m
Mouse 0.7 m 2 m 2–3 y >9 m >9 m >10 m
Quail 0.5 m 2 m 7–8 y 3–8 m 18 m 19 m
aTime span from the one-cell embryonic stage to death.
bThe infantile form.
m stands for months, y for years.
Analysis of RNA
RNA was isolated from cultured cells with RNAzol· according to
the manufacturer’s directions (Tel-Test). cDNA synthesis was
carried out using the Superscript pre-amplification system and
random hexamer-primers (Gibco BRL). The cDNA was PCR-
amplified with several primer combinations: m8 with m4
(antisense, TGGGTCCAGCGCACACACAGCT in exon 14)
amplifying a fragment including the neo cassette in the knockout
allele, n2 in the neo cassette in combination with m4 amplifying
the 3′ junction of the neo cassette and the Gaa gene, RT2
(GAACCAGTTCCTTCAGCTGT sense in exon 4) in combina-
tion with n1 (GTGTAGCGCCAAGTGCCAGCG antisense, in
the neo cassette). Primers AGGTCATCACCATCGGCAATG
(sense) and CGTCGTACTCCTGCTTGGTG (antisense) were
used for amplifying α-actin, a non-relevant control gene.
Acid α-glucosidase activity and protein assays
Mouse tissues were homogenized in phosphate-buffered saline
using an ultra turrax (TP 18–10, 20 000 Upm; 170 W, Janke &
Kunkel KG). After removal of the large debris at 10 000 g twice
for 15 min, the supernatant was stored at –20C. The supernatants
were assayed for α-glucosidase activity with 4MU as substrate
(40). The protein content of the supernatant was determined using
the bicinchoninic acid (BCA) protein assay (Pierce).
Western blotting
Acid α-glucosidase was immunoprecipitated from the homo-
genates with rabbit antibodies raised against human placental acid
α-glucosidase complexed to protein A–Sepharose 4B as
described (41). The Sepharose beads with the enzyme–immuno-
globulin complex bound to them were boiled in sample buffer and
applied to 10% SDS–PAGE. The proteins subsequently were
blotted onto nitrocellulose filters and visualized on these filters
with rabbit anti-human placental acid α-glucosidase antibodies
using the ECL detection kit (Amersham).
Immunocytochemistry
Acid α-glucosidase in cultured cells was visualized with rabbit
polyclonal antiserum raised against human placental acid
α-glucosidase in combination with goat anti rabbit IgG
conjugated to fluorescein isothiocyanate (FITC).
Histology
For routine histological examination, tissues were either frozen in
2-methylbutane chilled by liquid nitrogen or fixed in 2.5%
glutaraldehyde in 0.15 M cacodylate buffer and embedded in
glycolmethacrylate (GMA). Cryostat sections (6 µm) were stained
with haematoxylin–eosin (HE), PAS and acid phosphatase.
Alternatively, sections (2 µm) from GMA-embedded tissues were
PAS stained. For electron microscopy, glutaraldehyde-fixed tissues
specimens were post-fixed in 1% OsO4 with K3Fe(CN)6 in 0.1 M
cacodylate buffer according to De Bruijn (42). Standard pro-
cedures were used for epon embedding. Semi-thin (1 µm) and
ultrathin sections were cut on an LKB Nova ultratome and stained
with methylene blue (semi-thin) and uranylactate in combination
with Sato’s lead citrate (43) (ultrathin). Ultrathin sections were
examined in a Philips CM100 electron microscopy.
Cardiology 
Mice were anaesthetized with ether and pulsed radioscopies were
made (25/s) with a Siemens radiography apparatus. A surface
electrocardiogram (standard Einthoven) was obtained by sub-
cutaneous placement of 27-gauge needles in two front and one
hind limb. A 300 Hz filter was used. Data were recorded, digitized
on-line using a data acquisition program (WinDaq/ex; Dataq
Instrument, Inc., USA) and stored for post-acquisition off-line
analysis. The mice were killed with an overdose of hypnodil
(Janssen Pharmaceutica B.V.) for ex vivo comparison of gross
cardiac morphology.
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